Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/19324
Tipo
ArtículoDerechos de autor
Acceso restringido
Fecha del embargo
2030-01-01
Colecciones
- INI - Artigos de Periódicos [3498]
- IOC - Artigos de Periódicos [12793]
Metadatos
Mostrar el registro completo del ítem
RESPONSES OF LEISHMANIA (VIANNIA) BRAZILIENSIS CUTANEOUS INFECTION TO N-METHYLGLUCAMINE ANTIMONIATE IN THE RHESUS MONKEY (MACACA MULATTA) MODEL
Leishmania (Viannia) braziliensis
Cutaneous Infection
N-Methylglucamine Glucantime
Afiliación
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Imunologia. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Imunologia. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Imunologia. Rio de Janeiro, RJ. Brasil.
Resumen en ingles
The antileishmanial efficacy of the reference drug N-methylglucamine antimoniate (Glucantime) was evaluated in groups of rhesus monkeys with acute and chronic Leishmania (Viannia) braziliensis cutaneous infection. The therapeutic responses in experimental animals to either a low dose (5 mg/kg body wt/day for 28 days) or a routine dose (20 mg/kg/day for 28 days) of pentavalent antimony were similar to those reported in the human disease. Primates were cured of their lesions after treatment, but with cryptic parasitism and/or relapse. The rhesus model of L. (V.) braziliensis cutaneous leishmaniasis therefore provides an additional resource for preclinical trials with newer drugs.
Palabras clave en ingles
Rhesus MonkeyLeishmania (Viannia) braziliensis
Cutaneous Infection
N-Methylglucamine Glucantime
Compartir